The week in pharma: action, reaction and insight – week to March 14

16 March 2025

By Barbara Obstoj-Cardwell. Editor

The American Academy of Dermatology (AAD) meeting last week continued to provide positive news, including from US biotech Amgen and Japan’s Kyowa Kirin, with Phase III results for their rocatinlimab as a potential treatment for severe atopic dermatitis. In other news, Denmark’s Novo Nordisk released new data for its obesity hopeful CagriSema, which again failed to impress. Last week also saw US biotech 2seventy bio accept a takeover bid from Bristol Myers Squibb along with their partnered CAR-T cell therapy Abecma. Additionally, USA-based Sareum Holdings has in-licensed a cancer candidate, SRA737, from an unnamed company.

Surprising rocatinlimab (OX40R) updates

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK